Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 13 days ago

BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts

With significant upside potential, Structure Therapeutics Inc. (NASDAQ:GPCR) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites U... Full story

Yahoo Finance • 24 days ago

Structure Therapeutics reports Q3 results

* Structure Therapeutics press release [https://seekingalpha.com/pr/20297762-structure-therapeutics-reports-third-quarter-2025-financial-results-and-recent-highlights] (GPCR [https://seekingalpha.com/symbol/GPCR]): Q3 net loss for the th... Full story

Yahoo Finance • 24 days ago

Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation antic... Full story

Yahoo Finance • last month

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks.

Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones. Continue Reading View Comments... Full story

Yahoo Finance • last month

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

By Bhanvi Satija LONDON (Reuters) -Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war between Novo Nordisk and Pfizer, both vying for access to its pipeline of experi... Full story

Yahoo Finance • 2 months ago

Sum Up The Parts: ONEQ Could Be Worth $97

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • 3 months ago

Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill

Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ... Full story

Yahoo Finance • 4 months ago

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.

Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive positioning and Phas... Full story

Yahoo Finance • 5 months ago

We Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But whi... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics' SWOT analysis: oral GLP-1 stock poised for growth

Structure Therapeutics Inc. (NASDAQ:GPCR), a biopharmaceutical company specializing in the development of oral treatments for diabetes and obesity, has been making waves in the competitive GLP-1 receptor agonist market. With its lead candi... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics stock maintains JMP rating ahead of key data

Investing.com - JMP Securities maintained its Market Outperform rating and $89.00 price target on Structure Therapeutics (NASDAQ:GPCR) Monday. According to InvestingPro data, analysts’ price targets range from $37.50 to $120, with the stoc... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two... Full story

Yahoo Finance • 7 months ago

Eli Lilly Soars as Oral Diabetes Pill Hits Targets in Phase 3

Eli Lilly (NYSE:LLY) shares surged around 14% in premarket trading Thursday after the company reported positive Phase 3 trial results for orforglipron, its once-daily oral GLP-1 drug for type 2 diabetes. Warning! GuruFocus has detected 6... Full story

Yahoo Finance • 8 months ago

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk(NYSE: NVO), and Viking Therapeutics(NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's latest product announcement. Early this mo... Full story

Yahoo Finance • 10 months ago

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that... Full story

Yahoo Finance • last year

Is Structure Therapeutics Inc. (GPCR) the Best Young Stock To Buy Now?

We recently compiled a list of 10 Best Young Stocks To Buy Now. In this article, we will look at where Structure Therapeutics Inc. (NASDAQ:GPCR) ranks among the best young stocks to buy now. Market Uncertainty to Remain Until Elections A... Full story

Yahoo Finance • last year

Structure Therapeutics Appoints Angus C. Russell to Board of Directors

Structure Therapeutics Inc. Former Shire CEO brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc.... Full story